A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT05338775
- Locations
- πΊπΈ
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈColorado Blood Cancer Institute, Denver, Colorado, United States
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 201
- Registration Number
- NCT05327114
- Locations
- π«π·
Hospices Civils de Lyon HCL, Bron, France
π΅π±Clinical Research Center sp z o o MEDIC R s k, Poznan, Poland
πͺπΈHosp. Gral. Univ. de Alicante, Alicante, Spain
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 262
- Registration Number
- NCT05316155
- Locations
- πΊπΈ
Urology Associates, Nashville, Tennessee, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
πΊπΈUrology Associates of Denver, Lone Tree, Colorado, United States
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT05307692
- Locations
- πΊπΈ
Allied Biomedical Research Institute (ABRI), Inc, Miami, Florida, United States
πΊπΈQuantix Research, Miami, Florida, United States
πΊπΈEntrust Clinical Research, Miami, Florida, United States
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT05295927
- Locations
- πΊπΈ
GU Research Network, Omaha, Nebraska, United States
πΊπΈChesapeake Urology Research Associates, Towson, Maryland, United States
πΊπΈCarolina Urologic Research Center, Myrtle Beach, South Carolina, United States
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05275023
- Locations
- πͺπΈ
Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain
π¬π§Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom
π«π·Hopital Beaujon, Clichy, France
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
- Conditions
- Scalp PsoriasisPlaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT05272150
- Locations
- πΊπΈ
Tory P Sullivan M D PA, North Miami Beach, Florida, United States
π¨π¦Dermatology Research Institute Inc, Calgary, Alberta, Canada
πΊπΈTotal Skin and Beauty Dermatology Center, Birmingham, Alabama, United States
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
- Conditions
- Depression
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05268497
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
πΊπΈSheppard Pratt Health System, Baltimore, Maryland, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05265273
- Locations
- πΊπΈ
Penn State Milton S Hershey Medical Ctr, Hershey, Pennsylvania, United States
πΊπΈPhoenix Children's Hospital, Phoenix, Arizona, United States
πΊπΈChildrens Hospital Los Angeles, Los Angeles, California, United States
A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis
- Conditions
- Juvenile Psoriatic ArthritisArthritis, JuvenilePsoriasis
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT05252533
- Locations
- πΊπΈ
Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital, Chicago, Illinois, United States
πΊπΈCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
πΊπΈNewport Huntington Medical Group, Huntington Beach, California, United States